Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse
► Amphetamine-induced hyperactivity was attenuated by valproate or SB 216763. ► Valproic acid increased GSK3 phosphorylation in amphetamine-treated mice. ► Valproic acid and SB 216763 attenuated the development of amphetamine-induced sensitization. ► We conclude that GSK3 activation is important for...
Gespeichert in:
Veröffentlicht in: | Behavioural brain research 2012-05, Vol.231 (1), p.217-225 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 225 |
---|---|
container_issue | 1 |
container_start_page | 217 |
container_title | Behavioural brain research |
container_volume | 231 |
creator | Enman, Nicole M. Unterwald, Ellen M. |
description | ► Amphetamine-induced hyperactivity was attenuated by valproate or SB 216763. ► Valproic acid increased GSK3 phosphorylation in amphetamine-treated mice. ► Valproic acid and SB 216763 attenuated the development of amphetamine-induced sensitization. ► We conclude that GSK3 activation is important for amphetamine-induced hyperactivity and the development of sensitization to stereotypy.
Glycogen synthase kinase 3 (GSK3) is implicated in mediating dopamine-dependent behaviors. Previous studies have demonstrated the ability of amphetamine, which increases extracellular dopamine levels and influences behavior, to regulate the activity of GSK3. This study used valproic acid and the selective GSK3 inhibitor, SB 216763, to examine the role of GSK3 in amphetamine-induced hyperactivity and the development of sensitized stereotypic behavior. Pretreatment with valproic acid (50–300mg/kg, i.p.) or SB 216763 (2.5–5mg/kg, i.p.) prior to amphetamine (2mg/kg, i.p.) significantly reduced amphetamine-induced ambulation and stereotypy. To assess the development of sensitization to the stereotypic effects of amphetamine, mice were pretreated daily with valproic acid (300mg/kg) or SB 216763 (5mg/kg) prior to amphetamine (2mg/kg) for 5 days. Upon amphetamine challenge (1mg/kg) 7 days later, mice pretreated with valproate or SB 216763 showed a significant attenuation of amphetamine-induced sensitization of stereotypy. To determine whether regulation of GSK3 activity was associated with attenuation of acute amphetamine-induced hyperactivity by valproic acid, valproate (300mg/kg) or vehicle was injected prior to amphetamine (2mg/kg) or saline and brain tissue obtained. Analysis of the levels of phospho-GSK3α and β by immunoblot indicated that valproate increased phosphorylation of ser21-GSK3α in the frontal cortex, as well as ser9-GSK3β in the frontal cortex and caudate putamen of amphetamine-injected mice. These data support a role for GSK3 in acute amphetamine-induced hyperactivity and the development of sensitization to amphetamine-induced stereotypy. |
doi_str_mv | 10.1016/j.bbr.2012.03.027 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3566781</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166432812002227</els_id><sourcerecordid>22649795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c517t-51b087a9beef380b2a974828e731e8c583cec531084b0f2f5be543daee108edf3</originalsourceid><addsrcrecordid>eNp9kF1LHDEUhkNR6mr7A7yR_IEZ8zGZZCgURKwuFbzQ3jYkmTOdLE5mSbIL21_f6NalvfEqcPK-z-E8CJ1TUlNC28tVbW2sGaGsJrwmTH5AC6okq6RouiO0KJm2ajhTJ-g0pRUhpCGCfkQnjLVNJzuxQD-XYfTWZz8HPA_49vE7xyZnCBuTIWEzrUfIZvIBKh_6jYMej7s1ROOy3_q8wyb0OEFIBfHbvGJ8wHkEPM2bBJ_Q8WCeE3z--56hH99unq7vqvuH2-X11X3lBJW5EtQSJU1nAQauiGWmk41iCiSnoJxQ3IETnBLVWDKwQVgQDe8NQBlBP_Az9HXPXW_sBL2DkKN51uvoJxN3ejZe__8T_Kh_zVvNRdtKRQuA7gEuzilFGA5dSvSLbL3SRbZ-ka0J10V26Vz8u_TQeLNbAl_2ASinbz1EnZyHUCT6CC7rfvbv4P8AJeGTFA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Enman, Nicole M. ; Unterwald, Ellen M.</creator><creatorcontrib>Enman, Nicole M. ; Unterwald, Ellen M.</creatorcontrib><description>► Amphetamine-induced hyperactivity was attenuated by valproate or SB 216763. ► Valproic acid increased GSK3 phosphorylation in amphetamine-treated mice. ► Valproic acid and SB 216763 attenuated the development of amphetamine-induced sensitization. ► We conclude that GSK3 activation is important for amphetamine-induced hyperactivity and the development of sensitization to stereotypy.
Glycogen synthase kinase 3 (GSK3) is implicated in mediating dopamine-dependent behaviors. Previous studies have demonstrated the ability of amphetamine, which increases extracellular dopamine levels and influences behavior, to regulate the activity of GSK3. This study used valproic acid and the selective GSK3 inhibitor, SB 216763, to examine the role of GSK3 in amphetamine-induced hyperactivity and the development of sensitized stereotypic behavior. Pretreatment with valproic acid (50–300mg/kg, i.p.) or SB 216763 (2.5–5mg/kg, i.p.) prior to amphetamine (2mg/kg, i.p.) significantly reduced amphetamine-induced ambulation and stereotypy. To assess the development of sensitization to the stereotypic effects of amphetamine, mice were pretreated daily with valproic acid (300mg/kg) or SB 216763 (5mg/kg) prior to amphetamine (2mg/kg) for 5 days. Upon amphetamine challenge (1mg/kg) 7 days later, mice pretreated with valproate or SB 216763 showed a significant attenuation of amphetamine-induced sensitization of stereotypy. To determine whether regulation of GSK3 activity was associated with attenuation of acute amphetamine-induced hyperactivity by valproic acid, valproate (300mg/kg) or vehicle was injected prior to amphetamine (2mg/kg) or saline and brain tissue obtained. Analysis of the levels of phospho-GSK3α and β by immunoblot indicated that valproate increased phosphorylation of ser21-GSK3α in the frontal cortex, as well as ser9-GSK3β in the frontal cortex and caudate putamen of amphetamine-injected mice. These data support a role for GSK3 in acute amphetamine-induced hyperactivity and the development of sensitization to amphetamine-induced stereotypy.</description><identifier>ISSN: 0166-4328</identifier><identifier>EISSN: 1872-7549</identifier><identifier>DOI: 10.1016/j.bbr.2012.03.027</identifier><identifier>PMID: 22649795</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Amphetamine ; Amphetamine - pharmacology ; Animals ; Brain - drug effects ; Brain - metabolism ; Central Nervous System Stimulants - pharmacology ; Glycogen Synthase Kinase 3 - antagonists & inhibitors ; GSK3 ; Hyperactivity ; Hyperkinesis - chemically induced ; Hyperkinesis - metabolism ; Indoles - pharmacology ; Male ; Maleimides - pharmacology ; Mice ; Motor Activity - drug effects ; Phosphorylation - drug effects ; Sensitization ; Stereotyped Behavior - drug effects</subject><ispartof>Behavioural brain research, 2012-05, Vol.231 (1), p.217-225</ispartof><rights>2012 Elsevier B.V.</rights><rights>2012 Elsevier B.V. All rights reserved. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c517t-51b087a9beef380b2a974828e731e8c583cec531084b0f2f5be543daee108edf3</citedby><cites>FETCH-LOGICAL-c517t-51b087a9beef380b2a974828e731e8c583cec531084b0f2f5be543daee108edf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbr.2012.03.027$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22649795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Enman, Nicole M.</creatorcontrib><creatorcontrib>Unterwald, Ellen M.</creatorcontrib><title>Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse</title><title>Behavioural brain research</title><addtitle>Behav Brain Res</addtitle><description>► Amphetamine-induced hyperactivity was attenuated by valproate or SB 216763. ► Valproic acid increased GSK3 phosphorylation in amphetamine-treated mice. ► Valproic acid and SB 216763 attenuated the development of amphetamine-induced sensitization. ► We conclude that GSK3 activation is important for amphetamine-induced hyperactivity and the development of sensitization to stereotypy.
Glycogen synthase kinase 3 (GSK3) is implicated in mediating dopamine-dependent behaviors. Previous studies have demonstrated the ability of amphetamine, which increases extracellular dopamine levels and influences behavior, to regulate the activity of GSK3. This study used valproic acid and the selective GSK3 inhibitor, SB 216763, to examine the role of GSK3 in amphetamine-induced hyperactivity and the development of sensitized stereotypic behavior. Pretreatment with valproic acid (50–300mg/kg, i.p.) or SB 216763 (2.5–5mg/kg, i.p.) prior to amphetamine (2mg/kg, i.p.) significantly reduced amphetamine-induced ambulation and stereotypy. To assess the development of sensitization to the stereotypic effects of amphetamine, mice were pretreated daily with valproic acid (300mg/kg) or SB 216763 (5mg/kg) prior to amphetamine (2mg/kg) for 5 days. Upon amphetamine challenge (1mg/kg) 7 days later, mice pretreated with valproate or SB 216763 showed a significant attenuation of amphetamine-induced sensitization of stereotypy. To determine whether regulation of GSK3 activity was associated with attenuation of acute amphetamine-induced hyperactivity by valproic acid, valproate (300mg/kg) or vehicle was injected prior to amphetamine (2mg/kg) or saline and brain tissue obtained. Analysis of the levels of phospho-GSK3α and β by immunoblot indicated that valproate increased phosphorylation of ser21-GSK3α in the frontal cortex, as well as ser9-GSK3β in the frontal cortex and caudate putamen of amphetamine-injected mice. These data support a role for GSK3 in acute amphetamine-induced hyperactivity and the development of sensitization to amphetamine-induced stereotypy.</description><subject>Amphetamine</subject><subject>Amphetamine - pharmacology</subject><subject>Animals</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Central Nervous System Stimulants - pharmacology</subject><subject>Glycogen Synthase Kinase 3 - antagonists & inhibitors</subject><subject>GSK3</subject><subject>Hyperactivity</subject><subject>Hyperkinesis - chemically induced</subject><subject>Hyperkinesis - metabolism</subject><subject>Indoles - pharmacology</subject><subject>Male</subject><subject>Maleimides - pharmacology</subject><subject>Mice</subject><subject>Motor Activity - drug effects</subject><subject>Phosphorylation - drug effects</subject><subject>Sensitization</subject><subject>Stereotyped Behavior - drug effects</subject><issn>0166-4328</issn><issn>1872-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kF1LHDEUhkNR6mr7A7yR_IEZ8zGZZCgURKwuFbzQ3jYkmTOdLE5mSbIL21_f6NalvfEqcPK-z-E8CJ1TUlNC28tVbW2sGaGsJrwmTH5AC6okq6RouiO0KJm2ajhTJ-g0pRUhpCGCfkQnjLVNJzuxQD-XYfTWZz8HPA_49vE7xyZnCBuTIWEzrUfIZvIBKh_6jYMej7s1ROOy3_q8wyb0OEFIBfHbvGJ8wHkEPM2bBJ_Q8WCeE3z--56hH99unq7vqvuH2-X11X3lBJW5EtQSJU1nAQauiGWmk41iCiSnoJxQ3IETnBLVWDKwQVgQDe8NQBlBP_Az9HXPXW_sBL2DkKN51uvoJxN3ejZe__8T_Kh_zVvNRdtKRQuA7gEuzilFGA5dSvSLbL3SRbZ-ka0J10V26Vz8u_TQeLNbAl_2ASinbz1EnZyHUCT6CC7rfvbv4P8AJeGTFA</recordid><startdate>20120516</startdate><enddate>20120516</enddate><creator>Enman, Nicole M.</creator><creator>Unterwald, Ellen M.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20120516</creationdate><title>Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse</title><author>Enman, Nicole M. ; Unterwald, Ellen M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c517t-51b087a9beef380b2a974828e731e8c583cec531084b0f2f5be543daee108edf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Amphetamine</topic><topic>Amphetamine - pharmacology</topic><topic>Animals</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Central Nervous System Stimulants - pharmacology</topic><topic>Glycogen Synthase Kinase 3 - antagonists & inhibitors</topic><topic>GSK3</topic><topic>Hyperactivity</topic><topic>Hyperkinesis - chemically induced</topic><topic>Hyperkinesis - metabolism</topic><topic>Indoles - pharmacology</topic><topic>Male</topic><topic>Maleimides - pharmacology</topic><topic>Mice</topic><topic>Motor Activity - drug effects</topic><topic>Phosphorylation - drug effects</topic><topic>Sensitization</topic><topic>Stereotyped Behavior - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Enman, Nicole M.</creatorcontrib><creatorcontrib>Unterwald, Ellen M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Behavioural brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Enman, Nicole M.</au><au>Unterwald, Ellen M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse</atitle><jtitle>Behavioural brain research</jtitle><addtitle>Behav Brain Res</addtitle><date>2012-05-16</date><risdate>2012</risdate><volume>231</volume><issue>1</issue><spage>217</spage><epage>225</epage><pages>217-225</pages><issn>0166-4328</issn><eissn>1872-7549</eissn><abstract>► Amphetamine-induced hyperactivity was attenuated by valproate or SB 216763. ► Valproic acid increased GSK3 phosphorylation in amphetamine-treated mice. ► Valproic acid and SB 216763 attenuated the development of amphetamine-induced sensitization. ► We conclude that GSK3 activation is important for amphetamine-induced hyperactivity and the development of sensitization to stereotypy.
Glycogen synthase kinase 3 (GSK3) is implicated in mediating dopamine-dependent behaviors. Previous studies have demonstrated the ability of amphetamine, which increases extracellular dopamine levels and influences behavior, to regulate the activity of GSK3. This study used valproic acid and the selective GSK3 inhibitor, SB 216763, to examine the role of GSK3 in amphetamine-induced hyperactivity and the development of sensitized stereotypic behavior. Pretreatment with valproic acid (50–300mg/kg, i.p.) or SB 216763 (2.5–5mg/kg, i.p.) prior to amphetamine (2mg/kg, i.p.) significantly reduced amphetamine-induced ambulation and stereotypy. To assess the development of sensitization to the stereotypic effects of amphetamine, mice were pretreated daily with valproic acid (300mg/kg) or SB 216763 (5mg/kg) prior to amphetamine (2mg/kg) for 5 days. Upon amphetamine challenge (1mg/kg) 7 days later, mice pretreated with valproate or SB 216763 showed a significant attenuation of amphetamine-induced sensitization of stereotypy. To determine whether regulation of GSK3 activity was associated with attenuation of acute amphetamine-induced hyperactivity by valproic acid, valproate (300mg/kg) or vehicle was injected prior to amphetamine (2mg/kg) or saline and brain tissue obtained. Analysis of the levels of phospho-GSK3α and β by immunoblot indicated that valproate increased phosphorylation of ser21-GSK3α in the frontal cortex, as well as ser9-GSK3β in the frontal cortex and caudate putamen of amphetamine-injected mice. These data support a role for GSK3 in acute amphetamine-induced hyperactivity and the development of sensitization to amphetamine-induced stereotypy.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>22649795</pmid><doi>10.1016/j.bbr.2012.03.027</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0166-4328 |
ispartof | Behavioural brain research, 2012-05, Vol.231 (1), p.217-225 |
issn | 0166-4328 1872-7549 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3566781 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Amphetamine Amphetamine - pharmacology Animals Brain - drug effects Brain - metabolism Central Nervous System Stimulants - pharmacology Glycogen Synthase Kinase 3 - antagonists & inhibitors GSK3 Hyperactivity Hyperkinesis - chemically induced Hyperkinesis - metabolism Indoles - pharmacology Male Maleimides - pharmacology Mice Motor Activity - drug effects Phosphorylation - drug effects Sensitization Stereotyped Behavior - drug effects |
title | Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T13%3A27%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20GSK3%20attenuates%20amphetamine-induced%20hyperactivity%20and%20sensitization%20in%20the%20mouse&rft.jtitle=Behavioural%20brain%20research&rft.au=Enman,%20Nicole%20M.&rft.date=2012-05-16&rft.volume=231&rft.issue=1&rft.spage=217&rft.epage=225&rft.pages=217-225&rft.issn=0166-4328&rft.eissn=1872-7549&rft_id=info:doi/10.1016/j.bbr.2012.03.027&rft_dat=%3Cpubmed_cross%3E22649795%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/22649795&rft_els_id=S0166432812002227&rfr_iscdi=true |